Significance of C-Reactive Protein and Lysozyme in Crohn's Disease and Ulcerative Colitis Treated with Infliximab and Adalimumab

Inflammatory bowel diseases (IBD), namely Crohn's Disease and Ulcerative Colitis, are intestinal disorders that cause chronic inflammation of the digestive tract. The pathogenesis of the diseases is determined by environmental and disturbed immunological response on genetically predisposed persons. IBD causes physical and psychosocial consequences that can decrease the quality of life. Laboratory tests are of value in the management of IBD, such as C-Reactive Protein (CRP) and serum lysozyme. CRP levels serve as a marker for detecting IBD, differentiating it from functional bowel disorders, setting the disease severity and risk, and monitoring treatment's effectiveness. Lysozyme is a biomarker that can be used for additional screening in the diagnosis, prognosis, and management of IBD.